Oracle Runs

Oracle findings and outcome history for Efficacy and Safety Study of Tisotumab Vedotin for Patients With Solid Tumors (NCT03485209).

Runs

Findings

Latest Run

Apr 6, 2026, 2:57 PM

All Oracle Findings

Every stored oracle finding for this trial, including pending, dismissed, rejected, superseded, and accepted items.

NO_DECISIONDismissed90% confidenceGrok 4.20 (xAI)

Will the results be positive?

No public readout found for overall trial or specific indications (colorectal, pancreatic, NSCLC, HNSCC cohorts). Partial HNSCC data (Part C) shows ORR 16-32.5%, framed positively in sources as promising/encouraging activity, but not trial-wide, numeric-only, and lacks negative/overall framing. Trial active, primary completion 2026.

Found Apr 6, 2026, 2:59 PMReviewed Apr 6, 2026, 3:00 PM

Web Searchtargetedonc.comMar 2, 2022, 12:00 AM

Tisotumab Vedotin Shows Promising Efficacy in Phase 2 SCCHN

Phase 2 innovaTV 207 (NCT03485209) Part C SCCHN: confirmed ORR 16%, DCR 58%, tolerable safety; 79% target lesion reduction. Promising efficacy.

ClinicalTrialsclinicaltrials.gov

ClinicalTrials.gov NCT03485209

Active not recruiting. Objectives achieved, transition to LTEP. No results posted. Primary completion Mar 2026. Covers multiple parts/indications.

NO_DECISIONDismissed65% confidenceGrok 4.20 (xAI)

Will the results be positive?

HNSCC cohorts show encouraging ORR (16-32.5%) framed positively as 'encouraging antitumor activity'. No clear data or framing found for colorectal, NSCLC, or pancreatic cohorts in this multi-part Phase 2 basket trial (innovaTV 207). Primary completion 2026; results incomplete across indications.

Found Apr 6, 2026, 2:10 PMReviewed Apr 6, 2026, 2:19 PM

Web Searchbiospace.comJun 3, 2024, 12:00 AM

Investigational Tisotumab Vedotin Phase 2 Data Demonstrates Encouraging Antitumor Activity in Patients with Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (HNSCC)

Phase 2 innovaTV 207 (NCT03485209) Part C: 32.5% cORR in HNSCC; demonstrated encouraging antitumor activity as monotherapy.

Web Searchtargetedonc.comMar 2, 2022, 12:00 AM

Tisotumab Vedotin Shows Promising Efficacy and Manageable Toxicity Profile in Phase 2 Study of SCCHN

innovaTV 207 (NCT03485209): ORR 16%, DCR 58% in SCCHN; promising preliminary evidence of antitumor activity.

NO_DECISIONDismissed90% confidencemanual-chat-review

Will the results be positive?

ClinicalTrials.gov still lists this study as active not recruiting with no posted results, so there is not yet a clear public positive or negative trial readout.

Found Apr 4, 2026, 8:54 PMReviewed Apr 4, 2026, 10:33 PM

ClinicalTrialsclinicaltrials.govApr 1, 2026, 12:00 AM

Study Details | NCT03485209 | ClinicalTrials.gov

ClinicalTrials.gov lists active not recruiting; primary completion 2026-03-23; hasResults=false on the latest posted update.

NO_DECISIONDismissed88% confidenceGPT-5.4 (OpenAI)

Will the results be positive?

No clear overall trial-level readout yet. Publicly cited efficacy is for Part C only, which was described as encouraging in HNSCC, while the full Phase 2 basket study NCT03485209 remains active/not recruiting with primary completion listed for March 23, 2026.

Found Apr 1, 2026, 7:54 PMReviewed Apr 1, 2026, 7:55 PM

ClinicalTrialsclinicaltrials.gov

Study Details | NCT03485209 | Efficacy and Safety Study of Tisotumab Vedotin for Patients With Solid Tumors

ClinicalTrials.gov lists NCT03485209 as Active, not recruiting, with estimated primary completion March 23, 2026, indicating the overall Phase 2 basket trial has not reached a final public readout.

Web Searchglobenewswire.comJun 3, 2024, 12:00 AM

Investigational Tisotumab Vedotin Phase 2 Data Demonstrates Encouraging Antitumor Activity in Patients with Recurrent or Metastatic HNSCC

This public update is explicitly for innovaTV 207 Part C only and says the cohort showed encouraging antitumor activity in recurrent/metastatic HNSCC; it does not frame the entire NCT03485209 trial as overall positive.

Outcome History

Public history of accepted oracle reviews and recorded outcome changes for this trial.

No oracle outcome history is available for this trial yet.